OrthoTreat

OrthoTreat Overview

OrthoTreat believes in empowering healing from within, restoring strength and resilience to people affected by bone-related conditions. Our purpose is to transform lives by tackling one of the most complex challenges in medicine: true bone regeneration. We've formulated a unique approach, carefully overseeing and modulating the complex processes involved in bone regeneration. By creating a balanced system that precisely controls the immune response, inflammation, and growth factor secretion, we enable natural healing processes to work safely and effectively. Our flagship product, ModulX, is a dual-drug combination administered as a controlled-release, localized injection with minimal risk factors. ModulX’s sophisticated design accelerates healing, improves bone quality, and offers a new level of care for those in need. With this breakthrough, we’re setting a new standard in bone regeneration, supporting individuals globally in reclaiming mobility and quality of life.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 9, 2025 · ghpnews.digital

growth-positive

OrthoTreat 2024 Winner: Healthcare & Pharmaceuticals Awards

OrthoTreat has been recognized as the Most Pioneering Bone Regeneration Solutions Specialist for 2024 in the Healthcare & Pharmaceuticals Awards. The company focuses on addressing complex challenges in orthopedic medicine by promoting true bone regeneration. Their therapies aim to enhance natural healing, reduce complications, and prevent chronic disabilities, which can lower long-term care costs and reduce surgery rates. This recognition highlights OrthoTreats significant impact on healthcare systems worldwide, emphasizing their commitment to improving patient outcomes and healthcare efficiency.

May 8, 2024 · nocamels.com

growth-positive

New Gel Jab Aims To Help Broken Bones Heal Back Better 

OrthoTreat, a Tel Aviv-based startup, has developed ModulX, a gel-like therapy that enhances bone regeneration by up to 35%. The treatment is administered via injection at the fracture site and works by strengthening the bone and improving its psychological structure. The company has received funding from experts in orthopedics and sports professionals, and aims to complete human trials and enter the market by 2028. ModulX is designed to be affordable and effective, potentially reducing the need for surgical interventions. The therapy is currently in the clinical trial stage and is not yet FDA approved.

Product StageInvestment

Apr 23, 2022 · www.biopharma.coffee

growth-positive

19 Top BioPharma Startups & Companies (Tel Aviv)

The article discusses the BioPharma industry in Tel Aviv, highlighting the top companies and startups in the region. It mentions the impressive growth potential of the industry, with a 7.32% CAGR and a value of $325.17 billion in 2020. The article lists several BioPharma companies based in Tel Aviv, including CytoReason, InspireMD, PainReform, 101 Therapeutics, Treat Group, OWC Pharmaceutical Research, CTS Ltd, Xiologic, EndoStream, Ela Pharma, CannaPowder, ICB Biotechnology, Sebana Medical, OrthoTreat, Spero Biopharma, Zolex Therapeutics, ImmunoHiTech, BMR Solutions, and Nanoplate. The key theme of the article is the growth and potential of the BioPharma industry in Tel Aviv. The structured issues discussed in the article include customers, partners, and investment. The date of the event described in the article is not provided.

CustomersPartnersInvestment

Funding

Team Members

6

Employees: 11-50

Web & Social Links

Locations

HaPelech St 7, Tel Aviv-Yafo, Israel

Photos & Videos

No files yet

OrthoTreat Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info